Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Feb 16, 2015
FDA grants Neuren Orphan Drug designation for Rett syndrome
Feb 06, 2015
Appendix 3B
Feb 05, 2015
Change of Director's Interest Notice
Jan 29, 2015
Updated Share Trading Policy
Jan 28, 2015
Neuren announces trofinetide as proposed INN for NNZ-2566
Jan 27, 2015
Appendix 3B
Jan 22, 2015
Appendix 4C - quarterly
Jan 08, 2015
Investor Presentation, 8 January 2015
Jan 05, 2015
Response to ASX Price Query
Previous
1
2
3
4